Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

After a dramatic legal battle with Novo Nordisk ($NVO), U.S. low-cost healthcare services provider Hims & Hers ($HIMS) late last month began sellin...

Hims & Hers’ Shift to Branded Obesity Drugs Pressures Stock — Will the Bet Pay Off?

The latest update is out from Novo Resources ( ($TSE:NVO) ). Novo Resources will launch a series of drilling campaigns across its Wyloo, Cronus, Ba...

Novo Resources to Start Multi-Project Drill Campaign in Western Australia

Anthropic, the artificial intelligence (AI) firm behind Claude, has just bought a small biotech startup called Coefficient Bio for about $400 milli...

Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio

President Donald Trump on Thursday signed an executive order to impose a 100% tariff on imported branded medicines (patented drugs and their active...

AZN, NVO, NVS: What Does Trump’s New 100% Tariff Mean for Pharma Giants?

Shares in Danish drugmaking giant Novo Nordisk ($NVO) — already down about 26% since the start of the year — are now facing even more pressure afte...

Wegovy vs. Foundayo: Novo Nordisk’s “Record-Breaking” Run Meets the Eli Lilly (LLY) Challenge

The regulatory clearance has arrived sooner than expected. 


Eli Lilly Stock (LLY) Surges as FDA Approves Weight-Loss Pill

Scholar Rock Holding stock rallied on Tuesday alongside plans to resubmit a BLA for its spinal muscular atrophy treatment.


What Sent Scholar Rock Holding Stock (SRRK) Higher Today?

This week, several dividend stocks are trading close to their 52-week lows. Here is a list of ten such stocks that are also reaching their ex-divid...

Ex-Dividend Date Nearing for These 10 Stocks – Week of March 29, 2026

Markets React to Oil, Risk, and Rotation U.S. stocks moved lower last week as war risk and rising oil prices weighed on sentiment. The S&P 500 (SPX...

The Week That Was, The Week Ahead: Macro and Markets, Mar. 29

Low-cost healthcare services provider Hims & Hers ($HIMS) on Thursday disclosed the availability of approved versions of Novo Nordisk’s ($NVO) GLP-...

HIMS Stock Slides after Wegovy Subscription Launch; BofA Sees 31% Drop in GLP-1 Franchise

The latest update is out from Novo Nordisk ( ($NVO) ). Novo Nordisk held its Annual General Meeting in Bagsværd, Denmark, on 26 March 2026, approvi...

Novo Nordisk AGM Backs 2025 Dividend, Expands Capital Mandates and Refreshes Board

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Insmed (INSM), Addus Homecare (ADUS) and Novo Nord...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Addus Homecare (ADUS) and Novo Nordisk (NVO)

Indian drugmakers are preparing to launch generic versions of Novo Nordisk’s ($NVO) semaglutide treatments once the patent expires on Friday. In fa...

$14 Generic Wegovy Coming to India as Novo Nordisk (NVO) Patent Expires

Novo Nordisk received a Sell rating and price target from Bernstein analyst Justin Smith today. Smith covers the Healthcare sector, focusing on sto...

Novo Nordisk (0QIU) Receives a New Rating from Bernstein

Earnings, analysts updates, economic changes, and more are among the top stock market stories for Thursday.


Morning News Wrap-Up 3/19/26: Today’s Biggest Stock Market Stories

Novo Nordisk ($NVO) has secured U.S. FDA approval for Wegovy HD, a higher‑dose 7.2 mg version of its blockbuster weight‑loss drug. The new dose is ...

Novo Nordisk (NVO) Wins FDA Nod for High-Dose Wegovy amid Surging Obesity Drug Demand

Analysts are intrested in these 5 stocks: ( ($HIMS) ), ( ($NVO) ), ( ($CRWD) ), ( ($SEDG) ) and ( ($TU) ). Here is a breakdown of their recent


Hims, Novo, CrowdStrike, SolarEdge, Telus Trending With Analysts

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) has launched AMAZE 8, a Phase 3 study testing its new w...

Novo Nordisk’s AMAZE 8 Trial: A New Phase 3 Bet in Obesity and Diabetes

Shares of Hims & Hers Health ($HIMS) rose 6% in pre-market trading, extending a 58% gain over the past five days. The rally followed a deal with No...

Hims & Hers (HIMS) Stock Rallies 58% in Five Days — Can the Momentum Last?

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Novo Nordisk today and set a price target of DKK300.00. According to TipRanks, Holf...

Berenberg Bank Remains a Buy on Novo Nordisk (0QIU)

Hims & Hers ($HIMS) shares have been on a tear, up 49% since announcing a deal to sell Novo Nordisk’s ($NVO) weight-loss drugs Wegovy and Ozempic o...

HIMS-Novo ‘Can’t Quit Each Other’ – Bulls Rally on Wegovy Deal

The FDA has targeted the Danish company before. 


Market Cap	$164.80B	P/E Ratio	11.19
52W High	$81.44	52W Low	$35.12
Div Yield	255.0%	Payout Ratio	N/A
EPS Growth 3Y	29.7%	52W Position	5.4%
Overall Score	44	Value Score	70
Quality Score	44	Technical Score	18

EPS Current Est	$3.36	EPS Next Est	$3.41
EPS Growth Est	+1.5%	DPS Growth 3Y	29.9%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVO	$37.61	0.00%	13.82M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVO	$37.61	0%	13.82M
3
4
5
6

NVO

NVO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Novo Nordisk A/S Data in Excel

Get Novo Nordisk A/S Data in Excel